NanoString Technologies

NanoString Technologies, Inc. engages in the development and commercialization of instruments and services for profiling of genes and proteins from tissue sample. It offers the GeoMx Digital Spatial Profiler, nCounter Analysis System product platforms, GeoMx Assays, nCounter Panels & Assays and CosMx Spatial Molecular. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June, 2003 and is headquartered in Seattle, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

NanoString Technologies reports robust Q4 revenue and optimistic 2023 outlook

NanoString Technologies showcased strong Q4 2022 performance with revenue exceeding guidance and a positive outlook for 2023.
While facing challenges such as expected EBITDA losses and nCounter revenue decline, NanoString is leveraging opportunities in spatial biology and customer synergies.
The company's strengths lie in market-leading technology, positive customer feedback on CosMx instruments, and a cash-generating nCounter business.
Overall, NanoString's strategic focus on spatial biology and operational improvements position it for continued growth and innovation.

NanoString Technologies surpasses Q1 revenue targets, CosMx shines

NanoString Technologies had a strong Q1 2023, exceeding revenue guidance and raising full-year expectations.
Positive customer feedback and competitive positioning of CosMx in the spatial imager category are key strengths.
Challenges include EBITDA loss, capacity constraints, and shifts in product demand.
Opportunities lie in achieving cash flow breakeven, product growth, and market dominance with CosMx.

NanoString Technologies reports record Q2 revenue and strategic growth plans

NanoString Technologies delivered strong Q2 results, exceeding revenue guidance and showcasing growth in spatial biology.
The company's strategic objectives for 2023 focus on market expansion and product innovation, supported by a commitment to operational efficiency.
While facing challenges such as ongoing litigation and financial discussions, NanoString remains optimistic about its growth prospects and balance sheet strengthening.

NanoString Technologies achieves record revenue, eyes growth opportunities in 2024

NanoString Technologies reported strong revenue growth and cost reduction in Q3 2023.
Focus on spatial biology market penetration and new product offerings to drive future growth.
Legal challenges in Europe and backlog delays pose challenges to be addressed.
Improved gross margins and lower expenses expected to enhance profitability by 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString reports Q4 and FY21 operating results.

NanoString Technologies Releases Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook

SEATTLE--(BUSINESS WIRE)--NanoString to webcast presentation from the 42nd Annual Cowen Health Care conference.

NanoString to Webcast Presentation from the 42nd Annual Cowen Health Care Conference

SEATTLE--(BUSINESS WIRE)--NanoString to unveil CosMx™ Spatial Molecular Imager at the fourth annual virtual Spatial Genomics Summit on Monday, Feb. 28 from 8-10 a.m. (PST).

NanoString to Showcase CosMx Spatial Molecular Imager at 4th Annual Spatial Genomics Summit, Feb. 28

SEATTLE--(BUSINESS WIRE)--NanoString to present at 11th Annual SVB Leerink Healthcare Conference.

NanoString to Webcast Presentation from the 11th Annual SVB Leerink Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)--NanoString announces Q4/FY 21 conference call on Tue. March 1st.

NanoString to Release Fourth Quarter and Fiscal Year 2021 Operating Results and Host Conference Call on Tuesday, March 1, 2022

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today reported, as required by Nasdaq Stock Market Rules, an equity inducement award to John D. Gerace, the Company's new Chief Commercial Officer. In accordance with Nasdaq Listing Rule 5635(c)(4), NanoString's Compensation Committee approved the grant of the following equity award to Mr. Gerace as a material inducement to Mr. Gerace enterin

NanoString Reports Inducement Grant Under Nasdaq Listing Rules

NanoString Technologies Inc (NASDAQ: NSTG) expects Q4 FY21 product and service revenue of approximately $42 million, +18% Y/Y and at the upper end of the company's guidance of $38 million - $42 million. For FY21, the company expects product and service revenue to be approximately $144 million, +29% YY and at the upper end of the company's prior guidance of $140 million - $144 million.

NanoString Expects Q4 Product And Service Revenue Growth Of 18%

SEATTLE--(BUSINESS WIRE)--NanoString announces commercial leadership transition.

NanoString Announces Commercial Leadership Transition

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString announces preliminary Q4/FY21 operating results.

NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2021

SEATTLE--(BUSINESS WIRE)--NanoString to present at the 40th Annual JP Morgan Healthcare Conference.

NanoString to Webcast Presentation from the 40th Annual JP Morgan Healthcare Conference

SEATTLE--(BUSINESS WIRE)--NanoString announced the launch of the nCounter® TCR Diversity Panel and companion cloud-based TCR analysis report.

NanoString Launches nCounter TCR Diversity Panel and Analysis Package at the 2021 Annual Meeting of the Society for Immunotherapy of Cancer

NanoString Technologies Inc (NASDAQ: NSTG) reported Q3 sales of $37.15 million, +17% Y/Y, mainly driven by instrument sales, demand for consumables, and services. Q3 sales fell slightly short of analysts' consensus estimate of $37.79 million.

NanoString Technologies' Q3 Fall Short Street View; Cuts FY21 Guidance

SEATTLE--(BUSINESS WIRE)--NanoString to present at the 2021 Stifel Virtual Healthcare Conference.

NanoString to Webcast Presentation from the Stifel 2021 Virtual Healthcare Conference

NanoString Technologies' (NSTG) CEO Brad Gray on Q3 2021 Results - Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString reports third quarter 2021 operating results.

NanoString Releases Operating Results for Third Quarter of 2021

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the first public release of data generated by the CosMx™ Spatial Molecular Imager (SMI). The data represents the first high-plex, single cell in situ dataset from formalin-fixed paraffin-embedded (FFPE) tissue samples and is accompanied by the simultaneous publication of a manuscript describing the CosMx SMI technology and per

NanoString Releases High-Resolution FFPE Tissue Dataset Generated Using New CosMx Spatial Molecular Imager

SEATTLE--(BUSINESS WIRE)--Publication in the journal Cell reveals SARS-CoV-2 does not appear to affect the expression of odorant receptor genes.

NanoString's GeoMx Digital Spatial Profiler Used to Explore Loss of Smell Associated with COVID-19

SEATTLE--(BUSINESS WIRE)--NanoString Unveils Spatial Organ Atlas During the American Society of Human Genetics (ASHG) Conference.

NanoString Unveils Spatial Organ Atlas During the American Society of Human Genetics (ASHG) Conference

SEATTLE--(BUSINESS WIRE)--NanoString announces the launch of the nCounter® ADC Development Panel.

NanoString Launches nCounter Antibody Drug Conjugate Panel to Accelerate the Development of Oncology Treatments

SEATTLE--(BUSINESS WIRE)--NanoString to host third quarter 2021 operating results webcast on Tuesday, November 9th, 2021.

NanoString to Release Third Quarter 2021 Operating Results and Host Conference Call on Tuesday, November 9, 2021

SEATTLE--(BUSINESS WIRE)--NanoString to webcast presentation from Baird Global Healthcare Conference.

NanoString to Webcast Presentation from the Baird 2021 Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)--NanoString to present at Morgan Stanley Global Healthcare Conference.

NanoString to Webcast Presentation from the 19th Annual Morgan Stanley Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)--NanoString announced a peer-reviewed publication using the GeoMx® Digital Spatial Profiler (DSP), published in the journal Cell.

NanoString's GeoMx Digital Spatial Profiling Platform Reveals Insights Into the Immune Landscape of Cancer in Publication in the Journal Cell

NanoString Technologies, Inc. (NSTG) CEO Brad Gray on Q2 2021 Results - Earnings Call Transcript

NanoString (NSTG) delivered earnings and revenue surprises of -7.14% and 2.81%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

News for NanoString Technologies Stock (NSTG)